Zurich Cantonal Bank
PHAT icon

Zurich Cantonal Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Zurich Cantonal Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,890
Closed -$330K – 3257
2025
Q4 		$330K Buy
+19,890
New +$284K ﹤0.01% 2004

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Zurich Cantonal Bank's PHAT Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Phathom Pharmaceuticals (PHAT) stake by 3.4% in Q2 2026, buying an estimated $9.65K and bringing the position to 25,838 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2214.

Zurich Cantonal Bank first reported a position in PHAT in Q1 2023 and has held it in 11 quarters since. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Zurich Cantonal Bank held 25,838 shares of Phathom Pharmaceuticals worth $280K as of Q2 2026.
  • Zurich Cantonal Bank bought 846 Phathom Pharmaceuticals shares in Q2 2026, an estimated $9.65K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2214 holding.
  • Zurich Cantonal Bank first reported a position in Phathom Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.